scholarly journals Acute mesenteric vein thrombosis after endoscopic injection sclerotherapy for esophageal varices in a patient with liver cirrhosis

2019 ◽  
Vol 13 (2) ◽  
pp. 118-121 ◽  
Author(s):  
Le Wang ◽  
Xiangbo Xu ◽  
Yue Hou ◽  
Xiaodong Shao ◽  
Xiaozhong Guo ◽  
...  
Keyword(s):  
Liver Cirrhosis ◽  
Esophageal Varices ◽  
Injection Sclerotherapy ◽  
Endoscopic Injection Sclerotherapy ◽  
Endoscopic Injection ◽  
Mesenteric Vein Thrombosis ◽  
Mesenteric Vein ◽  
Vein Thrombosis

scholarly journals A case of liver cirrhosis with exaggerated portal vein thrombosis after endoscopic injection sclerotherapy(EIS) for esophageal varices.

Kanzo ◽  
1996 ◽  
Vol 37 (7) ◽  
pp. 393-399
Author(s):  
Yukio OHTSUKA ◽  
Nobyuoshi YANAGISAWA ◽  
Takeshi OINUMA ◽  
Keiko FUJIWARA ◽  
Atsushi MATSUTANI ◽  
...  
Keyword(s):  
Liver Cirrhosis ◽  
Portal Vein ◽  
Portal Vein Thrombosis ◽  
Esophageal Varices ◽  
Injection Sclerotherapy ◽  
Endoscopic Injection Sclerotherapy ◽  
Endoscopic Injection ◽  
Vein Thrombosis

scholarly journals Endoscopic injection sclerotherapy improves liver function compared with endoscopic variceal ligation

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Tsuguru Hayashi ◽  
Tatsuyuki Watanabe ◽  
Michihiko Shibata ◽  
Shinsuke Kumei ◽  
Shinji Oe ◽  
...  
Keyword(s):  
Liver Cirrhosis ◽  
Liver Function ◽  
Confidence Interval ◽  
Linear Regression Analysis ◽  
Meld Score ◽  
Injection Sclerotherapy ◽  
Endoscopic Variceal Ligation ◽  
Endoscopic Injection Sclerotherapy ◽  
Endoscopic Injection ◽  
Liver Functions

AbstractLiver function is a most important prognostic factor in patients with liver cirrhosis. Also, portal hypertension is a fatal complication of liver cirrhosis and variceal treatment is indispensable. However, changes of liver functions after endoscopic variceal treatments are unknown. The aim of this study was to evaluate prognosis and liver functions after endoscopic injection sclerotherapy (EIS) and endoscopic variceal ligation (EVL). A total of liver cirrhotic 103 patients who underwent prophylactic EIS and EVL were enrolled. Overall survival rate was higher in EIS group than EVL group (p = 0.03). Multivariate analysis showed that EIS was a negative factor for death (HR: 0.46, 95% confidence interval: 0.24–0.88, p = 0.02). Liver functions were assessed by blood test taken at before and 3 months after treatment. In EIS group, albumin and prothrombin time improved (p < 0.01), leading to improvement of Child–Pugh score, ALBI score and MELD score (p < 0.05). However, these did not improve in EVL group. EIS was a significant factor related to the elevated value of albumin after treatment in linear regression analysis (estimated regression coefficient: 0.17, 95% confidence interval: 0.05–0.29, p = 0.005). These results revealed that EIS could improve liver functions and prognosis.

Sign in / Sign up

Export Citation Format

Share Document